| Baseline (n = 21) | Flupirtine 3μM (n = 7) | Flupirtine 10 μM (n = 8) | Flupirtine 30 μM (n = 16) | XE 911 10μM (n = 9) | ANOVA (df)F, p | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Strength-duration time constant (ms) | 0.11 | ± | 0.02 | 0.19 | ± | 0.03 | 0.13 | ± | 0.02 | 0.10 | ± | 0.01 | 0.16 | ± | 0.03 | (3:43)2.00, 0.13 |
Rheobase (mA) | 8.53 | ± | 2.55 | 6.47 | ± | 2.89 | 6.50 | ± | 1.76 | 6.54 | ± | 1.16 | 9.35 | ± | 1.96 | (3:43)0.22, 0.88 |
Relative Refractory Period RRP (ms) | 4.40 | ± | 0.37 | 3.30 | ± | 0.16 | 2.83 | ± | 0.17* | 2.55 | ± | 0.13** | 3.67 | ± | 0.30 | (3:48)8.61, < 0.01 |
Refractoriness at 2 ms (%) | 76.61 | ± | 21.07 | 50.58 | ± | 18.13 | 42.74 | ± | 21.28 | 45.44 | ± | 21.86 | 44.03 | ± | 5.21 | (3:48)0.57, 0.64 |
Refractoriness at 2.5 ms (%) | 30.43 | ± | 5.63 | 18.69 | ± | 5.96 | 10.47 | ± | 7.16* | 3.19 | ± | 3.91** | 19.46 | ± | 4.29 | (3:48)5.39, < 0.01 |
Superexcitability at 5 ms (%) | −6.61 | ± | 1.92 | −14.04 | ± | 1.87 | −16.20 | ± | 1.18** | −19.00 | ± | 1.180** | −10.83 | ± | 2.30 | (3:48)11.56, < 0.01 |
Superexcitability at 7 ms (%) | −11.04 | ± | 1.72 | −16.74 | ± | 1.86 | −18.01 | ± | 1.27 | −20.25 | ± | 1.22** | −14.64 | ± | 2.11 | (3:48)7.31, < 0.01 |
Depolarisation TEd (90–100 ms) | 34.86 | ± | 1.81 | 32.48 | ± | 4.11 | 32.26 | ± | 3.04 | 32.33 | ± | 2.86 | 35.96 | ± | 2.33 | (3:47)0.27, 0.85 |
Hyperpolarisation TEh (90–100 ms) | −73.57 | ± | 6.79 | −72.99 | ± | 9.23 | −68.42 | ± | 5.44 | −85.15 | ± | 19.30 | −108.79 | ± | 32.65 | (3:47)0.27, 0.85 |